The effects of protein binding on the activities of caspofungin, anidulafungin, and micafungin were evaluated against Candida and Aspergillus species. Adding human serum sharply increased the MICs of micafungin and anidulafungin and modestly affected the MIC of caspofungin. The increase in MICs does not appear consistent with the rate of protein binding for the three compounds.
trays were prepared in advance by dispensing 100 l of serially diluted drug into 96-well microdilution plates and freezing the plates at Ϫ70°C. All three compounds were tested over a 20-fold dilution range from 64 to 0.00012 g/ml.
The MICs of test drugs with Candida species and Aspergillus species were determined using the broth microdilution variants of CLSI M27-A2 and CLSI M38-A (9), respectively. Testing was performed both in standard medium (RPMI 1640, 0.165 M MOPS, pH 7.0) and in standard medium containing 50% pooled human serum (Sigma, St. Louis, MO). To achieve this, inocula were standardized spectrophotometrically and diluted either with sterile water or with 100% pooled human serum to final concentrations of 1 ϫ 10 3 to 5 ϫ 10 3 yeast or 0.4 ϫ 10 4 to 5 ϫ 10 4 conidia. Then, 100-l volumes of these doublestrength inocula were added to the 100-l volumes of serially diluted drug in the microdilution trays. MICs of Candida and Aspergillus species were read after 24 and 48 h at 35°C as MIC-0, i.e., complete growth inhibition, and MIC-2, i.e., at least 50% growth inhibition. For Aspergillus, a minimum effective concentration was also determined microscopically (7) and found to be equivalent to the macroscopically determined MIC-2 reading. The MIC-2 readings are thus used for both fungal genera.
A line listing of the results seen after 24 h is shown in Table  1 . The qualitative effects of serum on echinocandin susceptibility were similar for Candida species at 24 and 48 h and using endpoints of MIC-0 and MIC-2 (not shown); thus, the 24-h MIC-2 results are shown as being characteristic of the entire data set. For Aspergillus species, all MIC-0 readings were offscale, and thus only the MIC-2 readings provide useful information; qualitative effects of serum on echinocandin susceptibility were similar at 24 and 48 h, as seen for Candida spp. A summary of the ratios of the MIC-2 values by time, genus, and drug is shown in Table 2 . The addition of 50% serum consistently elevated the observed MICs for anidulafungin and micafungin. For caspofungin, on the other hand, an increased MIC was observed for some (but not all) isolates, and this effect was never as frequent as or of the magnitude of that seen for the other two agents. An analysis of the effect of serum for Candida and Aspergillus species (Table 3) showed that the effect of serum was similar for each drug across the range of tested species.
In this study, we have extended prior work by testing a broad range of Candida and Aspergillus spp. and by directly comparing the effects of serum on all three echinocandins (2, 3, 4, 16; Eraxis package insert [Pfizer] ). The effect of serum was greatest for anidulafungin and micafungin, and this is entirely consistent with the results of prior studies on these two drugs (4, 16; Eraxis package insert [Pfizer] ). Prior work with caspofungin against single isolates of C. albicans (2) and A. fumigatus (3) found that serum had no effect against the Candida isolate and enhanced activity against the Aspergillus isolate. These results are consistent with the absence of effect of serum seen for some isolates in our survey, and we did not see any enhancing activity with the addition of serum.
In summary, we have observed that serum strongly affects the observed MICs of anidulafungin and micafungin and modestly affects the MIC of caspofungin. This rank order of effects does not appear consistent with the rank order of protein binding for the three compounds and is thus a further demonstration of the relatively unpredictable nature of the effect of serum on antifungal effect. As related examples, terbinafine (Ͼ99% protein bound [13] ) has a reduced in vitro potency in the presence of serum that has been correlated with reduced in (8, 11, 14) . On the other hand, although the potency of itraconazole (99.8% protein bound [6] ) does appear affected in vitro or in vivo by the presence of serum, protein binding does not impede the drug's activity (12, 13, 18) . For the echinocandin antifungal agents, the impact of these in vitro effects on in vivo activity is not yet understood and is likely not of clinical significance. However, we think that the different serum effects with these three echinocandins may explain the different dosage regimens of these drugs in clinical practice.
